drugset / Trial / NCT02283489
Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will investigate the efficacy and safety of recombinant human endostatin adenovirus combined with chemotherapy for advanced head and neck malignant tumors.
Timeline
- Start
- 2014-10
- Primary completion
- 2016-10
- Completion
- 2016-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | recombinant human endostatin adenovirus | Unknown | 5e+11 unknown | Other |
| Subject | recombinant human endostatin adenovirus | Unknown | 1e+12 unknown | Other |
| Background | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 160 mg/m2 | Intravenous |